Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of LXH254 combination regimens in previously treated BRAF V600- or NRAS-mutant metastatic melanoma
NL-OMON55115Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing LXH254 + LTT462, LXH254 + trametinib and LXH254 + ribociclib (3 arms). Primary endpoint: Objective response rate. Started Apr 2021; status: active, not recruiting.
02
Drugs
naporafenibrineterkibtrametinibribociclib
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON55115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55115.